Zachary Simmons
Overview
Explore the profile of Zachary Simmons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
3177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berry J, Maragakis N, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA
. 2025 Mar;
PMID: 40067821
Importance: Bioenergetic failure has been proposed as a driver of amyotrophic lateral sclerosis (ALS). CNM-Au8 is a suspension of gold nanocrystals that catalyzes the conversion of nicotinamide adenine dinucleotide hydride...
2.
Shefner J, Oskarsson B, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA
. 2025 Mar;
PMID: 40067755
Importance: Amyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention. Objective: To determine the effects of pridopidine, a σ1-receptor agonist, in...
3.
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial
Andrews J, Paganoni S, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA Neurol
. 2025 Mar;
PMID: 40067754
Importance: Myeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via...
4.
5.
Paganoni S, Fournier C, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2459058.
PMID: 39960672
Importance: The etiology of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, is unknown. However, neuroinflammation and complement activation may play a role in disease progression. Objective: To determine the...
6.
Bhai S, Levine T, Moore D, Bowser R, Heim A, Walsh M, et al.
Muscle Nerve
. 2024 Nov;
71(1):63-72.
PMID: 39511965
Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with no known cure, limited treatment options with minimal benefits, and significant unmet need for disease modifying therapies. Aims:...
7.
Lukac M, Luben H, Martin A, Simmons Z, Geronimo A
Digit Biomark
. 2024 Oct;
8(1):22-29.
PMID: 39473802
Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that alters gait and increases the risk of falls. The current model of care involves in-person multidisciplinary clinic visits to,...
8.
Walsh S, Simmons Z, Miyamoto S, Geronimo A
Amyotroph Lateral Scler Frontotemporal Degener
. 2024 Sep;
26(1-2):22-28.
PMID: 39258588
Objective: Health coaching may supplement the multidisciplinary ALS clinic model to facilitate patient-centered health behavior change. The aim of this study was to determine the effects of nurse health coaching...
9.
10.
Radakovic R, Carroll A, Altiero A, Reichwein C, Walsh S, Niven E, et al.
J Neurol
. 2024 Aug;
271(10):6822-6838.
PMID: 39196396
Background: Self-perceived quality of life (QoL) is important in amyotrophic lateral sclerosis (ALS). Although caregiver burden and strain have been related to cognitive and behavioural impairment, there has been no...